How many clinical trials are tracked for Tick-Borne Encephalitis?

5 trials are tracked, 2 with published results.

Tick-Borne Encephalitis Research

Tick-Borne Encephalitis: what the trials found

Vaccination for Tick-Borne Encephalitis (TBE) demonstrates high seropositivity rates across multiple study designs and formulations. Specifically, studies using FSME-IMMUN 0.25 mL Junior or 0.5 mL reported a 100% seropositivity rate via Neutralization Test (NT) at both 21-35 days and up to 46 months following the first booster vaccination ¹.

Inactivated TBE vaccines have shown high efficacy in inducing antibody responses; studies reported seropositivity rates of 97.8% to 100% via NT after the second dose, and 91% to 100% across various intervals following first and third doses ⁴. Additionally, a 0.5 mL TBE vaccine demonstrated a 98-100% seropositivity rate at 4 weeks after the third dose, with low rates of local reactions observed within 7 days of administration ³.

Monitoring of antibody titers shows high prevalence of detectable responses; studies reported that approximately 89.58% to 100% of subjects achieved TBE antibody titers ≥ 2, while 89.58% to 94.12% achieved titers ≥ 10 ².

For the clinician treating this condition

TBE vaccines consistently achieve high seropositivity rates (90-100%) across various dosages and testing methods (NT and ELISA) [1, 4].
Long-term immunity is supported by evidence of sustained seropositivity up to 46 months post-booster ¹.
Vaccine safety profiles indicate low rates of local reactions following administration ³.

AI synthesis of 5 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.